{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% CI was not estimable due to low number of events and longer observation time.","groupId":"OG000","lowerLimit":"17.2","upperLimit":"NA","value":"27.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"description":"OS was defined as the time between date of first dose and date of death due to any cause. Participants without an event were censored at the date last known to be alive. Participants without any follow-up information were censored at the date of first dose. The median time to the event was estimated using the methodology of Kaplan-Meier. Brookmeyer-Crowley method was used to calculate 95% CI.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG000","title":"Alectinib 600 mg (Fed): Phase II"}],"paramType":"MEDIAN","populationDescription":"Phase II safety population","reportingStatus":"POSTED","timeFrame":"Baseline up to death (any cause) (maximum follow up 284 weeks)","title":"Overall Survival (OS) Time: Phase II","type":"SECONDARY","unitOfMeasure":"months"}